Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Tel- Aviv, Israel Clinical Trials

A listing of Tel- Aviv, Israel clinical trials actively recruiting patients volunteers.

RESULTS

Found (812) clinical trials

Impact of Humira Therapy on Ocular Inflammation Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate Posterior and Panuveitis in Routine Clinical Practice

This study aims at evaluating real life effectiveness of originator adalimumab (Humira) participants with active non-infectious intermediate, posterior and panuveitis (NIIPPU) despite high-dose corticosteroid therapy; including effect on ocular inflammation, health-related quality of life, health resource utilization, work ability and medication burden, as well as describe the characteristics of NIIPPU ...

Phase N/A

0.0 miles

Learn More »

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

Study AG120-C-009 is a global, Phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of AG-120 (ivosidenib) + azacitidine vs placebo + azacitidine in adult subjects with previously untreated IDH1m AML who are considered appropriate candidates for non-intensive therapy. The primary endpoint is Overall Survival ...

Phase

0.0 miles

Learn More »

Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis

The primary objective of this study is to evaluate the efficacy of filgotinib versus placebo for the treatment of the signs and symptoms of noninfectious uveitis in participants failing treatment for active noninfectious uveitis.

Phase

0.0 miles

Learn More »

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma. The primary hypotheses of this study are that pembrolizumab plus chemotherapy is superior to placebo ...

Phase

0.0 miles

Learn More »

Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema

This 3-part study will evaluate the efficacy and safety of an oral kallikrein inhibitor, BCX7353, in the treatment angioedema attacks in subjects with Type I or II hereditary angioedema (HAE). In each study part, subjects will treat 3 attacks with BCX7353 (2 attacks) or placebo (1 attack), in a randomly ...

Phase

0.0 miles

Learn More »

A Study to Evaluate Safety and Effects of Sotagliflozin Dose 1 and Dose 2 on Glucose Control in Patients With Type 2 Diabetes Severe Impairment of Kidney Function and Inadequate Blood Sugar Control

The study duration is up to 60 weeks including 4 weeks prior to randomization, 52 weeks of randomized treatment and a visit 4 weeks after completion of the randomized treatment period.

Phase

0.0 miles

Learn More »

Safety and Efficacy Study of Sotagliflozin on Glucose Control in Patients With Type 2 Diabetes Moderate Impairment of Kidney Function and Inadequate Blood Sugar Control

The study duration is up to 60 weeks including 4 weeks prior to randomization, 52 weeks of randomized treatment, and a visit 4 weeks after completion of the randomized treatment period.

Phase

0.0 miles

Learn More »

Firazyr Patient Registry (Icatibant Outcome Survey - IOS)

The Firazyr and Cinryze patient registry is a multicenter, prospective, observational study for patients treated with Firazyr and/or Cinryze in countries where it is currently approved. The entry of participants in the Firazyr and Cinryze Registry is at the discretion of the physician and the participant and is not a ...

Phase N/A

0.0 miles

Learn More »

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian Fallopian Tube or Primary Peritoneal Cancer Patients

Rucaparib is an orally available, small molecule inhibitor of poly-adenosine diphosphate [ADP] ribose polymerase (PARP) being developed for treatment of ovarian cancer associated with homologous recombination (HR) DNA repair deficiency (HRD). The safety and efficacy of rucaparib has been evaluated in several Phase 1 and Phase 2 studies. An oral ...

Phase

0.0 miles

Learn More »

A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)

The purpose of this study is to determine whether Nivolumab is effective in the treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)

Phase

0.0 miles

Learn More »